Press Releases

    • MAR 29 2017

    MGH/Dana Farber Initiate Expansion of ONC201 Glioblastoma Trial

    Philadelphia, PA (March 29, 2017) – Oncoceutics, Inc. announced that Massachusetts General Hospital (MGH) and the Dana Farber Cancer Institute are now enrolling patients in an expansion of the clinical trial “Oral ONC201 in Adult Recurrent Glioblastoma”. The Phase II Trial, identified as NCT02525692 on, began in early 2016 with recurrent glioblastoma (GBM) patients

    • MAR 24 2017

    Oncoceutics Presentations on ONC201 and Other Imipridones at AACR 2017

    Philadelphia, PA (March 24, 2017) –Oncoceutics, Inc. announces that multiple abstracts from the company and its commercial and academic collaborators will be presented at the 2017 annual meeting of the American Association of Cancer Research (AACR) April 2nd – April 5th in Washington DC. These 15 abstracts highlight the anti-cancer activity and novel mechanisms of the

    • MAR 22 2017

    ONC201 Phase I Trial Results Reported in Clinical Cancer Research

    Philadelphia, PA (March 22, 2017) – Oncoceutics, Inc. announced the publication of an original research article in the journal Clinical Cancer Research entitled “First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors” that describes the Phase I trial of the company’s lead compound at the Rutgers Cancer Institute of New Jersey. The

    • MAR 14 2017

    Oncoceutics Expands DRD2 Research Collaborations with NIH

    Philadelphia, PA (March 14, 2017) – Oncoceutics, Inc., announced a number of new research collaborations with various groups within the National Institutes of Health (NIH) to study DRD2 as a novel therapeutic target in oncology. DRD2, a member of the dopamine receptor family that is part of the G protein-coupled receptor (GPCR) superfamily, is a